Paterna BioSciences HoldCo discloses Form D equity offering of $11.2 million
The Salt Lake City biotechnology company reported $6.3 million sold to 17 investors as of a July 30, 2026 first sale date, according to an SEC filing signed August 12, 2026.
Paterna BioSciences HoldCo Inc., a Delaware corporation incorporated in 2023 and based in Salt Lake City, Utah, filed a Form D with the SEC disclosing a new exempt securities offering. The filing lists a date of first sale of 2026-07-30 and is marked as a new notice rather than an amendment.1
The total offering amount is listed at $11,206,627, with $6,322,375 already sold and $4,884,252 remaining to be sold. The filing notes that the total offering amount figure includes a warrant valued at $743.27.1
The company reported 17 investors have already put money into the offering.1 Paterna is claiming the Rule 506(b) exemption under Regulation D.1 The securities being offered include equity and an option, warrant, or other right to acquire another security.1
The filing states the offering is not tied to a business combination such as a merger or acquisition. The company does not intend for the offering to last more than one year.1
Paterna identifies its industry as biotechnology within the health care sector.1 It selected "Decline to Disclose" for its revenue or net asset value range.1
The filing shows a minimum investment of $0, no sales compensation recipients, no sales commissions, no finders' fees, and no proceeds directed to executive officers, directors, or promoters.1
Related persons named in the filing include Alexander Pastuszak, listed as an executive officer and director, along with Daniel Mitchell as an executive officer, and directors James Hotaling, Cynthia Tsai, Ryan Morley, and Abraham Meir Rosenbaum.1 The form was signed by Alexander Pastuszak as CEO on 2026-08-12.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.